Neurocrine CFO sells 2,311 shares at $157

NBIX’s CFO reported PRSU vesting, related tax-share withholding, and a 10b5-1 plan sale of 2,311 shares at a weighted average price near $157 per share.

Rhea-AI Filing Summary

Neurocrine Biosciences Inc (NBIX) Chief Financial Officer Matt Abernethy reported a mix of equity award vesting, tax withholding, and open-market sales. On September 11, 2026, 5,020 shares of common stock were acquired upon vesting of performance restricted stock units after a performance metric was certified; on the same date, 2,709 shares were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements, with no shares sold in that transaction. On September 14, 2026, he sold 2,311 shares of common stock in transactions effected by a broker at a weighted average price of $157.1981 per share, under a Rule 10b5-1 trading plan, with individual sale prices ranging from $157.05 to $157.43 per share.

Insider Trade Summary 10b5-1

Net Seller: 2,311 shares

Net Sell 3 txns

Insider ABERNETHY MATT

Role Chief Financial Officer

Sold 2,311 shs ($363K)

Type	Security	Shares	Price	Value
Sale	Common Stock F3, F4	2,311	$157.1981	$363K
Grant/Award	Common Stock F1	5,020	$0.00	$0.00
Tax Withholding	Common Stock F2	2,709	$156.22	$423K

Holdings After Transaction: Common Stock — 42,808 shares (Direct)

Footnotes (4)

1. F1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
2. F2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
3. F3. The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
4. F4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.05 to $157.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Key Figures

PRSUs vested: 5,020 shares Shares withheld for taxes: 2,709 shares Shares sold: 2,311 shares +3 more

6 metrics

PRSUs vested 5,020 shares Performance restricted stock units vesting upon certification of a performance metric on September 11, 2026

Shares withheld for taxes 2,709 shares Shares withheld by Neurocrine Biosciences, Inc. on September 11, 2026 to satisfy tax withholding on PRSU vesting

Shares sold 2,311 shares Common stock sold on September 14, 2026 in open-market or private transactions

Weighted average sale price $157.1981 per share Average price for the 2,311 shares sold on September 14, 2026

Sale price range $157.05–$157.43 per share Price range of multiple transactions included in the September 14, 2026 sale

Rule 10b5-1 plan adoption date May 22, 2026 Date the trading plan governing the September 14, 2026 sale was adopted

Key Terms

performance restricted stock units (PRSUs), Rule 10b5-1 trading plan, tax withholding requirements

3 terms

performance restricted stock units (PRSUs) financial

"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest"

Rule 10b5-1 trading plan regulatory

"effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

tax withholding requirements financial

"Shares withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements on vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did NBIX’s CFO report on this Form 4?

The CFO reported vesting of 5,020 performance-based shares on September 11, 2026, withholding of 2,709 shares for taxes the same day, and a sale of 2,311 shares on September 14, 2026 at a weighted average price of $157.1981 per share.

How many Neurocrine Biosciences (NBIX) shares did the CFO sell and at what price?

He sold 2,311 shares of NBIX common stock on September 14, 2026 at a weighted average price of $157.1981 per share, in multiple trades with prices ranging from $157.05 to $157.43 per share.

Were the NBIX insider sales made under a Rule 10b5-1 trading plan?

Yes. The reported disposition of 2,311 shares on September 14, 2026 was effected by a broker pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2026, and the issuer’s policy restricts amending such plans after adoption.

What triggered the 5,020-share acquisition reported by the NBIX CFO?

The 5,020 shares reflect performance restricted stock units that were previously granted and vested when one performance metric was certified as achieved on September 11, 2026.

Were any of the NBIX shares withheld for tax purposes actually sold in the market?

No. The 2,709 shares reported with transaction code F on September 11, 2026 were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements on PRSU vesting, and the disclosure states that no shares were sold in that transaction.

What is the role of the reporting person in Neurocrine Biosciences (NBIX)?

The reporting person, Matt Abernethy, is identified as the Chief Financial Officer of Neurocrine Biosciences Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 05:03 PM Accepted by SEC EDGAR 09/15/2026 - 05:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ABERNETHY MATT

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		A(1)		5,020	A	$0	47,828	D
Common Stock	09/11/2026		F(2)		2,709	D	$156.22	45,119	D
Common Stock	09/14/2026		S(3)		2,311	D	$157.1981(4)	42,808	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

3. The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.05 to $157.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)